Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families.
about
Multiple Pituitary Adenomas: A Systematic ReviewStructure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal α-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma PredispositionGermline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study.Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers.The immunophilin-like protein XAP2 is a negative regulator of estrogen signaling through interaction with estrogen receptor αFamilial isolated pituitary adenomas: from genetics to therapy.In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantismRegulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas.Familial pediatric endocrine tumors.Aryl Hydrocarbon Receptor Interacting Protein Targets IRF7 to Suppress Antiviral Signaling and the Induction of Type I Interferon.Do the aryl hydrocarbon receptor interacting protein variants (Q228K and Q307R) play a role in patients with familial and sporadic hormone-secreting pituitary adenomas?Clinical and genetic aspects of familial isolated pituitary adenomasFamilial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations.Gene mutations in Cushing's disease.Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland.Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenomaThe genetic background of acromegaly.Familial isolated pituitary adenomas: an emerging clinical entity.The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas.Genetic mutations in sporadic pituitary adenomas--what to screen for?The role of genetic and epigenetic changes in pituitary tumorigenesis.MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro.Genetics of gigantism and acromegaly.Familial acromegaly due to aryl hydrocarbon receptor-interacting protein (AIP) gene mutation in a Turkish cohort.Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening.Should aip gene screening be recommended in family members of FIPA patients with R16H variant?AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation.AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience.Familial pituitary adenomas - who should be tested for AIP mutations?Risk category system to identify pituitary adenoma patients with AIP mutations.Aryl Hydrocarbon Receptor-Interacting Protein (AIP) N-Terminus Gene Mutations Identified in Pituitary Adenoma Patients Alter Protein Stability and Function.Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation.A novel C-terminal nonsense mutation, Q315X, of the aryl hydrocarbon receptor-interacting protein gene in a Japanese familial isolated pituitary adenoma family.A novel germline mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene in an Italian family with gigantism.Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland.In vivo bioassay to test the pathogenicity of missense human AIP variants.Frequency of familial pituitary adenoma syndromes among patients with functioning pituitary adenomas in a reference outpatient clinic.Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant?
P2860
Q26766458-8E9A4724-7B40-4A37-B086-BD9D878DC9E1Q27675839-FAC3704A-BFE0-492D-9BE9-4A97C42E7DDBQ30276702-4863DAEB-321A-45C5-960A-2EBCC352A422Q30370834-A76B6889-3816-4737-8AC9-FBB7F6300196Q30473787-F52A3333-2EEF-4D1D-BA1A-1E4DD53FBF2BQ33713409-9A5CEE4B-573D-406F-855E-A296BE932C56Q33904569-B38FB9F5-BB48-4E63-B8AB-7FE23D5199E2Q35057730-EDACE75B-BA4C-4E09-8C95-C5EC87D2546BQ35584367-0EF7624B-7BD0-4E1B-9B7B-197586EACB7DQ35860858-9D7DD6D6-430A-4D1E-B0FB-9E5E65B2141FQ35865197-D42FAD4F-CBE2-42A4-9C11-7DC21F66A56BQ35895480-40BFB3CB-EC85-42BA-A1CD-D814FF3F0756Q36724063-01E57E21-0D38-4F5E-9BD6-C54DDEC8926EQ36991419-7058DC26-5E42-45CA-A34C-CE8EC56ECD06Q37147499-F078700F-F40D-40C1-BD30-0C0845B73A53Q37204404-BBBCBC4D-ABFC-4292-95F0-0326026516B4Q37561016-C2903A4A-236F-49D6-8176-5842BF9882A3Q37619445-134A83AE-9DD8-4DF9-A632-E76385A6DE90Q37678059-0211C712-BF5E-4D3F-8E6F-A72729F0B324Q38073256-A91EF04D-1C22-4ED7-BAD6-0992619860B5Q38173701-9D812A14-605A-4D98-B6CB-DBE1CFF8F3FDQ38263242-884785C5-7645-4809-A180-B6A089CC46C1Q38274982-8D794126-9928-4A33-A3C7-46908366DF59Q38323442-A85FA944-AEAB-4B09-9DFB-C2D7797635BDQ38961684-F0CEE57B-8520-4554-8C59-072403BC6CBAQ42439620-4AB15DB7-05E6-4041-8E91-76F02BF7B431Q42749595-6963B08B-B099-4016-ABB4-907B2D891DA7Q43569673-501EFBD3-7E06-49E1-B687-41D68FAE249CQ47124521-DEBDCA5F-4222-4E06-B813-D5FB128E77E6Q47322124-7E98EF45-C739-4564-87ED-E90DE07C3691Q47735880-80856E66-2D26-4F3C-98F1-5253519B203DQ50027224-6215DEA4-FDC0-49CA-8163-2CDAC13A838DQ51113867-9504C2D9-3B1B-4510-9E02-B4648B59AC9BQ52608079-137EF550-EC3F-43BE-920A-9F3FBF1A8112Q52649896-D8333A71-A124-452E-9F23-F520BB402B52Q52651698-6BEA5A31-D399-4725-9942-BECEF9270451Q52672961-986C5A83-5723-4BB1-A836-815E1485C916Q52720533-EEB2815D-92B5-4441-A208-7CF6A9486F32Q53173053-C4044AD8-A325-4EFD-B223-DED1E3ACD73FQ53487796-311B1314-9951-49E0-8135-A24491285B10
P2860
Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Characterization of aryl hydro ...... ed pituitary adenoma families.
@ast
Characterization of aryl hydro ...... ed pituitary adenoma families.
@en
Characterization of aryl hydrocarbon receptor interacting protein
@nl
type
label
Characterization of aryl hydro ...... ed pituitary adenoma families.
@ast
Characterization of aryl hydro ...... ed pituitary adenoma families.
@en
Characterization of aryl hydrocarbon receptor interacting protein
@nl
prefLabel
Characterization of aryl hydro ...... ed pituitary adenoma families.
@ast
Characterization of aryl hydro ...... ed pituitary adenoma families.
@en
Characterization of aryl hydrocarbon receptor interacting protein
@nl
P2093
P2860
P50
P356
P1433
P1476
Characterization of aryl hydro ...... ed pituitary adenoma families.
@en
P2093
Ajith V Kumar
Ashley B Grossman
Bernard Khoo
Graeme B Bolger
Harvinder S Chahal
International FIPA Consortium
J Paul Chapple
Karen Stals
Katie Guegan
Maria Gueorguiev
P2860
P304
P356
10.1002/HUMU.21292
P577
2010-08-01T00:00:00Z